Ignite Creation Date:
2024-05-06 @ 12:25 AM
Last Modification Date:
2024-10-26 @ 10:50 AM
Study NCT ID:
NCT01576367
Status:
COMPLETED
Last Update Posted:
2018-09-11
First Post:
2012-02-17
Brief Title:
Efficacy Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes Familial Cold Autoinflammatory Syndrome Muckle-Wells Syndrome or Neonatal Onset Multisystem Inflammatory Disease
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Neonatal Onset Multisystem Inflammatory Disease |
| Cryopyrin-associated Periodic Syndromes |
| Familial Cold Autoinflammatory Syndrome |
| Muckle-Wells Syndrome |
Keywords:
| Name | View |
|---|---|
| childhood immunizations vaccinations | View |
| Cryopyrin-associated periodic syndromes CAPS | View |
| Familial Cold Autoinflammatory Syndrome FCAS | View |
| Muckle-Wells Syndrome MWS | View |
| Neonatal Onset Multisystem Inflammatory Disease NOMID | View |
| children systemic autoinflammatory disease | View |
| CIAS-1 gene | View |
| NALP-3 | View |
| NLRP3 | View |
| ACZ885 | View |
| canakinumab | View |
| human monoclonal anti-human interleukin-1 antibody | View |
| autosomal dominant | View |
| familial autoinflammatory syndrome | View |